dPCR And qPCR Market Development And Future Trends
Summary
- Major factors influencing the growth of the market.
- Leading players & Top Segments.
- Geographic Overview.
Market growth influenced due to following factors-
- Rising incidence of target infectious diseases and genetic disorders.
- Technological advancements in PCR technologies.
- Increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics.
- Successful completion of the Human Genome Project are driving the growth of this market.
Global market size-
According to the new market research report dPCR and qPCR market is projected to reach $7.6 billion by 2025, at a CAGR of 9.0% .
Leading Players -
The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).
Top Market Segments -
Based on products & services, the market is categorized into reagents and consumables, instruments and software & services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time)
Based on application, the market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications. The clinical applications segment is estimated to dominate the qPCR applications market in 2020.
For More Details, Download PDF Brochure
Geographic Overview -
North America accounted for the largest share of the dPCR and qPCR market, followed by Europe in 2019. The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R&D funding for genomic research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.